mewburn-logo-white mewburn-logo
  • About us
    • About us
    • Working with our Munich Office
    • Our AI Strategy & Action Plan
    • Who we work with
    • How we work with our clients
    • The Mewburn Ellis culture
    • Community giving
    • Inclusion & diversity
      • Inclusion & diversity
      • Gender Pay Gap
      • Women in IP
    • Sustainability
    • Join Mewburn Ellis
      • Join Mewburn Ellis
      • Vacancies
    • Graduate training programme
    • Business partners
      • Business partners
      • Code of conduct
      • Diversity policy
      • Environmental policy
  • Our People
    • Our People
    • View All People
    • Our Leadership Team
  • About you
    • Who we work with
    • I'm an attorney/law firm
    • I'm a university/R&D
    • I'm a corporate
    • I'm an SME
    • I'm a start up/spin out
  • Which service?
    • Services
    • I want to patent an invention
      • I want to patent an invention
      • Chemistry Patents
      • Engineering Patents
      • Life Sciences Patents
      • Patent Disputes
      • Patent Renewals
      • European Patent Validations
      • Pharma Patent Extensions & Regulatory Exclusivity
    • I want to protect a brand
      • I want to protect a brand
      • Register a trade mark
      • Trade mark disputes
      • Trade mark renewals
      • I want to change a domain name
    • I want to protect my design
      • Register a Design
      • Design Renewals
    • I need help with contentious proceedings
      • Contentious proceedings
      • post grant proceedings
      • oppositions or appeals
      • IP litigation or disputes
      • The Unified Patent Court
    • I need some commercial advice
    • I need to validate my European patent
    • I want to renew my ip rights
  • Spotlight on
    • Health
      • Advanced therapeutics
      • Animal health
      • Bioinformatics
      • BioProcessing & Industrial BioTech
      • Digital Health
      • Future food
      • Medical technologies
      • Microbiome
      • Pharmaceuticals
      • Plants
      • Precision medicine
      • Speciality pharma
    • Technology
      • Artificial Intelligence (AI)
      • Bioinformatics
      • BioProcessing & Industrial BioTech
      • Digital Health
      • Future mobility
      • Green & sustainable technologies
      • Medical technologies
      • New Nuclear Technologies
      • Quantum Technology
      • Software
      • Space Technology
    • Industry
      • 2d materials
      • Automotive
      • Energy storage
      • Green tech
      • Marine & ocean engineering
      • Medical devices
      • Polymers
      • Pharmaceuticals
      • Plants
      • Speciality pharma
      • Synthetic biology
    • Intellectual property
      • Brexit
      • Green ip
      • Ip litigation
      • Oppositions - chemistry & materials
      • Oppositions - engineering & ICT
      • Oppositions - life sciences
      • UPC
      • Women in ip
  • Knowledge hub
    • Law & practice library
    • News, insights & features
    • Special reports
    • Films
    • Events and Webinars
  • Contact us
    • Offices
      • 8 Bishopsgate
    • Residencies
  • en
  • zh-hans
  • germany
  • ja
  • ko
  • About us
    • About us
    • Working with our Munich Office
    • Our AI Strategy & Action Plan
    • Who we work with
    • How we work with our clients
    • The Mewburn Ellis culture
    • Community giving
    • Inclusion & diversity
      • Inclusion & diversity
      • Gender Pay Gap
      • Women in IP
    • Sustainability
    • Join Mewburn Ellis
      • Join Mewburn Ellis
      • Vacancies
    • Graduate training programme
    • Business partners
      • Business partners
      • Code of conduct
      • Diversity policy
      • Environmental policy
  • Our People
    • Our People
    • View All People
    • Our Leadership Team
  • About you
    • Who we work with
    • I'm an attorney/law firm
    • I'm a university/R&D
    • I'm a corporate
    • I'm an SME
    • I'm a start up/spin out
  • Which service?
    • Services
    • I want to patent an invention
      • I want to patent an invention
      • Chemistry Patents
      • Engineering Patents
      • Life Sciences Patents
      • Patent Disputes
      • Patent Renewals
      • European Patent Validations
      • Pharma Patent Extensions & Regulatory Exclusivity
    • I want to protect a brand
      • I want to protect a brand
      • Register a trade mark
      • Trade mark disputes
      • Trade mark renewals
      • I want to change a domain name
    • I want to protect my design
      • Register a Design
      • Design Renewals
    • I need help with contentious proceedings
      • Contentious proceedings
      • post grant proceedings
      • oppositions or appeals
      • IP litigation or disputes
      • The Unified Patent Court
    • I need some commercial advice
    • I need to validate my European patent
    • I want to renew my ip rights
  • Spotlight on
    • Health
      • Advanced therapeutics
      • Animal health
      • Bioinformatics
      • BioProcessing & Industrial BioTech
      • Digital Health
      • Future food
      • Medical technologies
      • Microbiome
      • Pharmaceuticals
      • Plants
      • Precision medicine
      • Speciality pharma
    • Technology
      • Artificial Intelligence (AI)
      • Bioinformatics
      • BioProcessing & Industrial BioTech
      • Digital Health
      • Future mobility
      • Green & sustainable technologies
      • Medical technologies
      • New Nuclear Technologies
      • Quantum Technology
      • Software
      • Space Technology
    • Industry
      • 2d materials
      • Automotive
      • Energy storage
      • Green tech
      • Marine & ocean engineering
      • Medical devices
      • Polymers
      • Pharmaceuticals
      • Plants
      • Speciality pharma
      • Synthetic biology
    • Intellectual property
      • Brexit
      • Green ip
      • Ip litigation
      • Oppositions - chemistry & materials
      • Oppositions - engineering & ICT
      • Oppositions - life sciences
      • UPC
      • Women in ip
  • Knowledge hub
    • Law & practice library
    • News, insights & features
    • Special reports
    • Films
    • Events and Webinars
  • Contact us
    • Offices
      • 8 Bishopsgate
    • Residencies
  • All topics
  • Forward
  • Artificial Intelligence
  • Battery Technologies
  • Bioinformatics
  • Brexit
  • Chemistry
  • Commercial Advice
  • Community
  • COVID-19
  • Designs
  • Energy Storage
  • Engineering
  • EU Unitary Patent / Unified Patent Court
  • FemTech
  • Future Food Tech
  • Future Mobility
  • Graphene & 2D Materials
  • Green Tech
  • ICT
  • Life Sciences
  • Litigation
  • Marine & Ocean Engineering
  • Materials
  • MedTech
  • Microbiome
  • Nature based materials
  • Nuclear
  • On-Demand
  • Oppositions
  • Patents
  • Pharmaceuticals
  • Plants
  • Polymers
  • Polymer recycling
  • Precision Medicine
  • Quantum Computing
  • SME
  • Software
  • Space Tech
  • Synthetic Biology
  • Trade Marks
Revolutionising Immunotherapy: The Promise of TCR T-Cells
Katherine Collins - February 19, 2025

Revolutionising Immunotherapy: The Promise of TCR T-Cells

For the past 10 years or so, the focus in the adoptive T-cell therapy space has been on chimeric ...

GENE-ius options to protect gene therapies
Anna Mudge - October 29, 2024

GENE-ius options to protect gene therapies

Gene therapies involve treating patients by manipulating their genetic makeup. Such therapies may ...

‘It’s a 50% reduction in ageing’
Adam Gregory - August 13, 2024

‘It’s a 50% reduction in ageing’

Singapore startup VVB Bio promises a dramatic reduction in ageing via a single jab. Now out of ...

Efficiency in Expansion: Meeting the Scale-Up Challenge in Cell and Gene Therapies
Katherine Collins - April 2, 2024

Efficiency in Expansion: Meeting the Scale-Up Challenge in Cell and Gene Therapies

One of the pivotal challenges in the development and commercialisation of cell and gene therapies ...

Cellular Agriculture – Innovating through the Challenges
Nick Sutcliffe - March 4, 2024

Cellular Agriculture – Innovating through the Challenges

The last year (2023) has seen a difficult environment for Cellular Agriculture (Cell Ag) companies ...

Top marks for Iovance as FDA approves first-in-class cell therapy Amtagvi for solid tumours
Katie Dale - February 26, 2024

Top marks for Iovance as FDA approves first-in-class cell therapy Amtagvi for solid tumours

On February 16, 2024, a real milestone was reached in the cell therapy field, as the FDA approved ...

Swapping in stem cells for diabetes treatment
Katie Dale - November 6, 2023

Swapping in stem cells for diabetes treatment

With just under 50% of type 1 diabetes patients using wearable blood glucose monitors1, medical ...

In vivo expression of chimeric antigen receptors: using gene therapy to improve cell therapy
Fay Allen - August 10, 2023

In vivo expression of chimeric antigen receptors: using gene therapy to improve cell therapy

In vivo CAR therapies build on the success of standard CAR treatments and aim to overcome the ...

The next-generation therapies for autoimmune diseases
Anna Mudge - August 9, 2023

The next-generation therapies for autoimmune diseases

The immune system has an extraordinary capacity to distinguish “self” from “non-self”. This means ...

Cells as medicines: the promise of cell therapy
Edward Couchman - August 7, 2023

Cells as medicines: the promise of cell therapy

Cell therapy is one of the most exciting areas of medical science, with recent years having seen ...

IP priorities for forward-looking cell and gene therapy businesses
Nick Sutcliffe - July 26, 2023

IP priorities for forward-looking cell and gene therapy businesses

IP priorities are especially important to businesses developing advanced therapeutic products. ...

The allogeneic advantage
Anna Mudge - May 4, 2023

The allogeneic advantage

Bespoke cell therapies are expensive and time-consuming. Now allogeneic cell treatments offer a ...

Advanced Therapies Congress 2023 - five key themes
Anna Mudge - March 21, 2023

Advanced Therapies Congress 2023 - five key themes

Anna Mudge enjoyed a bustling two days at the Advanced Therapies Congress 2023 in London. Nine ...

Trafficking T cells – how to get cells to their target destination
Anna Mudge - February 20, 2023

Trafficking T cells – how to get cells to their target destination

After being in the shadow of its famous relative, the antibody-producing B cell, for many decades, ...

CAR Treg cell therapy - to autoimmunity and beyond
Katie Dale - January 21, 2023

CAR Treg cell therapy - to autoimmunity and beyond

A new wave of cell therapy is hitting the clinics for treating various autoimmune diseases, by ...

A world-first approval for off-the-shelf cell therapy
Katherine Collins - December 23, 2022

A world-first approval for off-the-shelf cell therapy

We are delighted to learn that this week the European Commission granted the world’s first approval ...

We need to talk about women's health - spotlight on endometriosis
Fay Allen - March 8, 2022

We need to talk about women's health - spotlight on endometriosis

Women’s health is an area that has suffered from gender bias for years. One reason for this is that ...

Senolytics are knock, knock, knocking on ageing’s door
Daniel Yin - July 28, 2021

Senolytics are knock, knock, knocking on ageing’s door

In 1974, Bob Dylan asked that we stay forever young. Today, exciting developments in the longevity ...

First human in vivo CRISPR/Cas9 gene editing results make history
Joseph Morgan - July 19, 2021

First human in vivo CRISPR/Cas9 gene editing results make history

The ability to directly edit a patient’s genome safely and efficiently to treat genetic diseases ...

Cell therapy: repairing and rebuilding the body
Edward Couchman - June 15, 2021

Cell therapy: repairing and rebuilding the body

Recent advances in medicine have, for the first time, allowed physicians to directly intervene in ...

Jim Mellon: the reluctant gradualist taking on ageing
Adam Gregory - April 19, 2021

Jim Mellon: the reluctant gradualist taking on ageing

Forward editor Caitlin Mackesy Davies learns how we might all be able to live long and prosper from ...

Need to know: are we set for a bioprinting boom?
Isobel Stone - April 7, 2021

Need to know: are we set for a bioprinting boom?

From refashioning foods to fabricating organs, bioprinting is the smart technology that could have ...

The future of organ transplantation: growing organs from scratch?
Lucy White - March 31, 2021

The future of organ transplantation: growing organs from scratch?

Organ transplantation has saved, transformed, and extended countless lives. Although ...

Neoantigens: IP considerations for an emerging class of cancer immunotherapy
Frances Salisbury - September 10, 2020

Neoantigens: IP considerations for an emerging class of cancer immunotherapy

Recent cell and gene therapy product approvals have allowed the pharmaceutical industry to start a ...

Cellular immunity – a contributor to COVID-19 “dark matter”?
Rebecca Tollervey - June 25, 2020

Cellular immunity – a contributor to COVID-19 “dark matter”?

Immunologist Karl Friston of University College London has theorized that there may be ...

Neoantigen-targeted adoptive cell therapies – the next frontier in cancer immunotherapy
Anna Mudge - March 31, 2020

Neoantigen-targeted adoptive cell therapies – the next frontier in cancer immunotherapy

Cancer immunotherapies harness the power of the patient’s immune system to destroy malignant cells ...

Gamma/delta T cells emerge as an untapped resource for cancer immunotherapy
Eliot Ward - December 6, 2019

Gamma/delta T cells emerge as an untapped resource for cancer immunotherapy

Third lymphocyte lineage shows its mettle B lymphocytes, a type of white blood cell that is ...

T cell engagers - dark horses of immunotherapy
Adam Gregory - September 26, 2019

T cell engagers - dark horses of immunotherapy

Chimeric antigen receptor (CAR) technology has attracted a lot of attention and investment in ...

More

  • Slavery Act
  • Legal Notices
  • Terms and Conditions
  • Privacy
  • Forward Community Programme
  • Client Login
  • Join Mewburn Ellis

Follow us

Subscribe

Sign up to Forward: news, insights and features from Mewburn Ellis

Contact

  • mail@mewburn.com
  • London:

    +44 (0)20 7776 5300
  • Bristol:

    +44 (0)117 945 1234
  • Cambridge:

    +44 (0)1223 420383
  • Manchester:

    +44 (0)161 2477 722
  • Munich:

    +49 (0)89 244 459800

Copyright © 2025 Mewburn Ellis. All rights reserved. Terms and Conditions & Online Privacy